SciSparc subsidiary NeuroThera advances MDMA-PEA patent with Clearmind for PTSD
A newly published U.S. patent application covers combining MDMA with N-acylethanolamines like PEA, as FDA's new psychedelics guidance also names MDMA as a covered drug class.
SciSparc Ltd. (Nasdaq: SPRC) announced on August 24, 2026 that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) disclosed progress in its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND). The companies said a U.S. patent application has been published covering a combination of MDMA and N-acylethanolamines, such as palmitoylethanolamide (PEA), for use in treating post-traumatic stress disorder, anxiety, and eating disorders.1 The application was published by the U.S. Patent and Trademark Office.1
The companies said the collaboration integrates NeuroThera's PEA technology into Clearmind's psychedelic-derived therapeutic programs, and that the joint portfolio now includes thirteen published patent applications generated through the collaboration globally.1 The newly published application covers potential uses of PEA in combination with MDMA, including possible effects on MDMA's therapeutic potency, dosing requirements, side effects, and therapeutic window.1
The announcement also referenced a broader regulatory development. On July 14, 2026, the FDA finalized guidance titled "Psychedelic Drugs: Considerations for Clinical Investigations."1 The guidance lays out considerations for sponsors developing psychedelic drugs to treat conditions including psychiatric disorders and substance use disorders.1 The guidance places MDMA within a category described as encompassing entactogens or empathogens, alongside classic psychedelics. It addresses clinical trial design, conduct, data collection, subject safety, and new drug application requirements, and notes that psychedelic drugs can pose distinct development challenges due to their psychoactive effects on mood, cognition, and perception.1
SciSparc said the FDA's explicit inclusion of MDMA in the guidance gives regulatory context to the NeuroThera-Clearmind MDMA-PEA intellectual property.1 The company noted that forward-looking statements in the release are subject to risks detailed in its annual report filed with the SEC earlier this year and in later regulatory filings.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.